Galileo Biotech’s Post

🚨 Exciting updates from The BioHub! 🚨 Next week, we have an EXCLUSIVE episode featuring Spur Therapeutics. We'll dive into their rebrand from Freeline and their acquisition of SwanBio Therapeutics. Thankyou Michael Parini for joining us! 🎙️ Don't miss out! Episode drops next Wednesday. Stay tuned! #BioHubPodcast #Biotech #Pharma #Innovation #Podcast

🔥 The BioHub's First Ever Exclusive! 🔥 Big news from Freeline Therapeutics! They've rebranded as Spur Therapeutics and just acquired SwanBio Therapeutics! 🌟 What a huge week! Next week, we've got no other than the CEO of Spur, Michael Parini, joining us to discuss these game-changing developments! This is an episode you absolutely cannot miss. Stay tuned! 🎧 #BioHubPodcast #Exclusive #GeneTherapy #SpurTherapeutics #Innovation #MichaelParini #AvetixGroup

Thoughts on this? >> Early-stage oncology startup Boundless Bio files for IPO >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #biotech #pharmaceutical

#fundingalert 💼Company: Attovia Therapeutics 💰Funding: $105Million ⚡Round: Series B 👥Investors: Goldman Sachs Alternatives, Cormorant Asset Management, LP, Nextech Ventures, Redmile Group, EcoR1 Capital, LLC, Marshall Wace, and Logos Capital. Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages ATTOBODY™, a biparatopic biologics platform, to generate binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. The financing will be used to advance the Company’s lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the Company’s immunology and inflammation pipeline, and to further develop the ATTOBODY™ platform. Tao Fu, Colin Walsh, PhD, Hubert Chen, Zaneta Odrowaz, Petter Veiby , Hangjun Zhan Read more - https://lnkd.in/gyK-kDfU To share your startup story write us on - contact@startuprise.io #AttoviaTherapeutics #inflammation #biparatopic #immunology #funding #fundingnews #news #startup #startupnews

Forbion-backed biotech VectorY has raised a massive series A funding of $138M to develop a novel drug treatment for ALS. The way ALS is now managed, from diagnosis to prognosis, is still not ideal despite many studies. Early diagnosis can help ALS patients live longer since prompt treatment can halt the disease's development. Two medications, Sanofi riluzole and Mitsubishi Tanabe Pharma America edaravone, have recently been licensed for use in therapy, and they very slightly increase life expectancy. Great to see more funds getting behind MND/ALS drug development creating more awareness about the whole sector and the lack of treatment options for patients with this serious debilitating disease. #ALS #biotech #Amyotrophiclateralsclerosis #CNS #Neurodegenrative #seriesa #funding

Check out Proactive's research note that delves into some of our key programmes, each targetting large addressable markets such as #oncology, #flu, #RSV, #obesity and more.   The piece also covers our recent collaboration with a Nasdaq listed biopharma💊 using our oral delivery technology.   Read it here ⬇️ https://lnkd.in/epAmzseE

Here at GENICOS, our rallying cry when working with advanced therapeutics brands is braving new science. What does braving new science mean to Senior Project Planner Lauren Campbell? See below. #BravingNewScience #AdvancedTherapeutics #GENICOS

Macrocyclic drugs seem to be an area getting investment dollars these days -- Circle Pharma, Inc., a #UCSF - #UCSantaCruz spinoff with QB3 roots, just raised $54 million as part of a Series D. Circle is developing cyclin inhibitors for solid tumors. As mentioned in this Endpoints News story, Vilya, Orbis Medicines, and Bakar Labs tenant Insamo, all pursuing some form of macrocycles, all recently won funding. "Small molecule drugs can struggle with certain targets, such as the protein-protein interactions behind a wide range of diseases, including cancer. Antibodies, which boast that specificity, can’t be given as a pill. Macrocycles, however, can potentially bind very specific targets and they can be delivered in pill form." https://lnkd.in/dBk_adUB

Builders 🧱 w/ Thomas Miller - Co-Founder & CEO @ Iambic Therapeutics Tom Miller is a scientist and entrepreneur with focus on the nexus of AI, chemistry, and biology. He spent over 10 years as a tenured professor at Caltech, publishing more than 130 peer-reviewed articles and patents and receiving numerous awards for research excellence. Tom is co-founder and CEO of Iambic Therapeutics - previously known as Entos AI - disrupting the therapeutics landscape with a unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and seasoned drug hunters with strong track records of success in delivering clinically validated drugs. The Iambic platform has been demonstrated to deliver best-in-class and first-in-class development candidates to clinic with unprecedented speed and across multiple target classes and mechanisms of action. Iambic has recently announced an oversubscribed $100m Series B raise to demonstrate that the company’s lead programs deliver clinical efficacy for patients with urgent unmet need. See our latest episode below... https://buff.ly/48QzyjW #AIinMedicine #MicrofluidicsTech #BiologicalDiscovery #LifeSciencesAdvancement #TranslationalResearch #DiagnosticTesting #Therapeutics #BiotechInnovation #STEMAdvancement

Builders 🧱 w/ Tom Miller - Co-Founder & CEO @ Iambic Therapeutics Tom Miller is a scientist and entrepreneur with focus on the nexus of AI, chemistry, and biology. He spent over 10 years as a tenured professor at Caltech, publishing more than 130 peer-reviewed articles and patents and receiving numerous awards for research excellence. Tom is co-founder and CEO of Iambic Therapeutics - previously known as Entos AI - disrupting the therapeutics landscape with a unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and seasoned drug hunters with strong track records of success in delivering clinically validated drugs. The Iambic platform has been demonstrated to deliver best-in-class and first-in-class development candidates to clinic with unprecedented speed and across multiple target classes and mechanisms of action. Iambic has recently announced an oversubscribed $100m Series B raise to demonstrate that the company’s lead programs deliver clinical efficacy for patients with urgent unmet need. See our latest episode below... https://buff.ly/48QzyjW #AIinMedicine #MicrofluidicsTech #BiologicalDiscovery #LifeSciencesAdvancement #TranslationalResearch #DiagnosticTesting #Therapeutics #BiotechInnovation #STEMAdvancement